+

WO2005005453A3 - Novel compounds and compositions comprising sterols and/or stanols and cholesterol biosynthesis inhibitors and use thereof in treating or preventing a variety of diseases and conditions. - Google Patents

Novel compounds and compositions comprising sterols and/or stanols and cholesterol biosynthesis inhibitors and use thereof in treating or preventing a variety of diseases and conditions. Download PDF

Info

Publication number
WO2005005453A3
WO2005005453A3 PCT/CA2004/000999 CA2004000999W WO2005005453A3 WO 2005005453 A3 WO2005005453 A3 WO 2005005453A3 CA 2004000999 W CA2004000999 W CA 2004000999W WO 2005005453 A3 WO2005005453 A3 WO 2005005453A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
cholesterol biosynthesis
stanols
sterols
diseases
Prior art date
Application number
PCT/CA2004/000999
Other languages
French (fr)
Other versions
WO2005005453A2 (en
Inventor
James P Kutney
Haydn P Pritchard
Tatjana Lukic
Original Assignee
Forbes Medi Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forbes Medi Tech Inc filed Critical Forbes Medi Tech Inc
Priority to JP2006517922A priority Critical patent/JP2007525470A/en
Priority to BRPI0412439-1A priority patent/BRPI0412439A/en
Priority to AU2004255285A priority patent/AU2004255285A1/en
Priority to MXPA06000326A priority patent/MXPA06000326A/en
Priority to NZ545087A priority patent/NZ545087A/en
Priority to CA002531836A priority patent/CA2531836A1/en
Priority to EP04737936A priority patent/EP1644399A2/en
Publication of WO2005005453A2 publication Critical patent/WO2005005453A2/en
Publication of WO2005005453A3 publication Critical patent/WO2005005453A3/en
Priority to NO20060632A priority patent/NO20060632L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides, in one aspect, novel compounds comprising sterols and/or stanols and cholesterol biosynthesis inhibitors, including salts of these compounds and solvates and prodrugs of these compounds and/or salts. In another aspect, the present invention provides compositions comprising at least one sterol and/or stanol ester and at least one cholesterol biosynthesis inhibitor. Also provided are methods of treating or preventing a variety of diseases, conditions and disorders by administering the compounds or compositions provided herein.
PCT/CA2004/000999 2003-07-09 2004-07-09 Novel compounds and compositions comprising sterols and/or stanols and cholesterol biosynthesis inhibitors and use thereof in treating or preventing a variety of diseases and conditions. WO2005005453A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
JP2006517922A JP2007525470A (en) 2003-07-09 2004-07-09 Novel compounds and compositions comprising sterols and / or stanols and cholesterol biosynthesis inhibitors and their use in the treatment or prevention of various diseases and conditions
BRPI0412439-1A BRPI0412439A (en) 2003-07-09 2004-07-09 compounds and compositions comprising sterols and / or stanols and cholesterol biosynthesis inhibitors and their use in the treatment or prevention of a variety of diseases and conditions.
AU2004255285A AU2004255285A1 (en) 2003-07-09 2004-07-09 Novel compounds and compositions comprising sterols and/or stanols and cholesterol biosynthesis inhibitors and use thereof in treating or preventing a variety of diseases and conditions.
MXPA06000326A MXPA06000326A (en) 2003-07-09 2004-07-09 Novel compounds and compositions comprising sterols and/or stanols and cholesterol biosynthesis inhibitors and use thereof in treating or preventing a variety of diseases and conditions.
NZ545087A NZ545087A (en) 2003-07-09 2004-07-09 Novel compounds and compositions comprising sterols and/or stanols and cholesterol biosynthesis inhibitors and use thereof in treating or preventing a variety of diseases and conditions
CA002531836A CA2531836A1 (en) 2003-07-09 2004-07-09 Novel compounds and compositions comprising sterols and/or stanols and cholesterol biosynthesis inhibitors and use thereof in treating or preventing a variety of diseases and conditions.
EP04737936A EP1644399A2 (en) 2003-07-09 2004-07-09 Novel compounds and compositions comprising sterols and/or stanols and cholesterol biosynthesis inhibitors and use thereof in treating or preventing a variety of diseases and conditions.
NO20060632A NO20060632L (en) 2003-07-09 2006-02-09 New compounds and compositions comprising sterols and / or stanols and cholesterol biosynthesis inhibitors and their use in the treatment or prevention of a variety of diseases and conditions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61545603A 2003-07-09 2003-07-09
US10/615,456 2003-07-09

Publications (2)

Publication Number Publication Date
WO2005005453A2 WO2005005453A2 (en) 2005-01-20
WO2005005453A3 true WO2005005453A3 (en) 2005-06-09

Family

ID=34062381

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2004/000999 WO2005005453A2 (en) 2003-07-09 2004-07-09 Novel compounds and compositions comprising sterols and/or stanols and cholesterol biosynthesis inhibitors and use thereof in treating or preventing a variety of diseases and conditions.

Country Status (13)

Country Link
EP (1) EP1644399A2 (en)
JP (1) JP2007525470A (en)
KR (1) KR20060052792A (en)
CN (1) CN1832957A (en)
AU (1) AU2004255285A1 (en)
BR (1) BRPI0412439A (en)
CA (1) CA2531836A1 (en)
MX (1) MXPA06000326A (en)
NO (1) NO20060632L (en)
NZ (1) NZ545087A (en)
PL (1) PL379516A1 (en)
RU (1) RU2006103797A (en)
WO (1) WO2005005453A2 (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010500300A (en) 2006-08-08 2010-01-07 サノフィ−アベンティス Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for their preparation, agents containing these compounds, and uses thereof
KR100886466B1 (en) * 2006-09-12 2009-03-04 (주)한국씨엔에스팜 Novel stigmasterol derivatives or pharmaceutically acceptable salts thereof, preparation methods thereof, and compositions for preventing and treating obesity or hyperlipidemia comprising the same
DE102007005045B4 (en) 2007-01-26 2008-12-18 Sanofi-Aventis Phenothiazine derivatives, process for their preparation and their use as medicines
EP2025674A1 (en) 2007-08-15 2009-02-18 sanofi-aventis Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs
DE102007054497B3 (en) 2007-11-13 2009-07-23 Sanofi-Aventis Deutschland Gmbh New crystalline hydrate form of dodecanedioic acid 4-((2S,3R)-3-((S)-3-(4-fluoro-phenyl)-3-hydroxy-propyl)-2-(4-methoxy-phenyl)-4-oxo-azetidin-1-yl)-benzylamide ((2S,3R,4R,5R)-pentahydroxy-hexyl)-amide useful e.g. to treat hyperlipidemia
US8470841B2 (en) 2008-07-09 2013-06-25 Sanofi Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
MX2012001729A (en) 2009-08-26 2012-06-13 Sanofi Sa Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use.
WO2011157827A1 (en) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683699B1 (en) 2011-03-08 2015-06-24 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120057A1 (en) 2011-03-08 2012-09-13 Sanofi Novel substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683701B1 (en) 2011-03-08 2014-12-24 Sanofi Oxathiazine derivatives substituted with benzyl or heteromethylene groups, method for their preparation, their usage as medicament, medicament containing same and its use
WO2012120052A1 (en) 2011-03-08 2012-09-13 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
WO2012120050A1 (en) 2011-03-08 2012-09-13 Sanofi Novel substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
EP2683700B1 (en) 2011-03-08 2015-02-18 Sanofi Tetra-substituted oxathiazine derivatives, method for their preparation, their usage as medicament and medicament containing same and its use
US8809325B2 (en) 2011-03-08 2014-08-19 Sanofi Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US9717742B2 (en) 2012-05-07 2017-08-01 The Regents Of The University Of California Oxysterol analogue OXY133 induces osteogenesis and hedgehog signaling and inhibits adipogenesis
KR20140081339A (en) * 2012-12-21 2014-07-01 부경대학교 산학협력단 Pharmaceutical composition for prevention or treatment of neurodegenerative disease comprising fucosterol
CA2911205A1 (en) 2013-05-02 2014-11-06 The Regents Of The University Of California Bone-selective osteogenic oxysterol-bone targeting agents
EP3229809B1 (en) 2014-12-09 2019-11-27 Warsaw Orthopedic, Inc. Compounds and methods involving sterols
CN104434927A (en) * 2014-12-16 2015-03-25 吉林农业大学 Application of bicyclopentanoperhydrophenanthrene malonate B in preparing hypotensive drugs
US9877836B2 (en) 2015-07-10 2018-01-30 Warsaw Orthopedic, Inc. Compression resistant implants including an oxysterol and methods of use
US9987289B2 (en) 2015-07-10 2018-06-05 Warsaw Orthopedic, Inc. Slow release oxysterols and methods of use
US10632230B2 (en) 2015-07-10 2020-04-28 Warsaw Orthopedic, Inc. Implants having a high drug load of an oxysterol and methods of use
US12171909B2 (en) 2015-07-10 2024-12-24 Warsaw Orthopedic, Inc. Implants having a drug load of an oxysterol and methods of use
CN105055404B (en) * 2015-08-19 2017-07-18 四川大学 Purposes of the HMGCS2 inhibitor in the medicine for preparing treatment cocaine habituation
CN105087609B (en) * 2015-08-19 2018-10-23 四川大学 A kind of recombinant slow virus and its purposes in the drug for preparing treatment cocaine habituation
US10688222B2 (en) 2016-11-21 2020-06-23 Warsaw Orthopedic, Inc. Lyophilized moldable implants containing an oxysterol
US11384114B2 (en) 2016-12-09 2022-07-12 Warsaw Orthopedic, Inc. Polymorphic forms of an oxysterol and methods of making them
US10434106B2 (en) * 2017-05-19 2019-10-08 Warsaw Orthopedic, Inc. Oxysterol-statin compounds for bone growth
US11464888B2 (en) 2017-06-12 2022-10-11 Warsaw Orthopedic, Inc. Moldable formulations containing an oxysterol in an acellular tissue matrix
KR102139994B1 (en) * 2017-10-25 2020-07-31 대구대학교 산학협력단 Pharmaceutical composition for use in preventing or treating osteoporosis containing stigmasterol as an active ingredient
CN113143935B (en) * 2021-02-01 2022-10-11 广东药科大学 Application of stigmasterol in the preparation of drugs for improving cardiac hypertrophy

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5216015A (en) * 1991-02-05 1993-06-01 Rhone-Poulenc Rorer Pharmaceuticals Inc. Compounds having hypocholesterolemic properties
WO2001000653A1 (en) * 1999-06-23 2001-01-04 Forbes Medi-Tech Inc. Conjugates of phytosterol or phytostanol with ascorbic acid and use thereof in treating or preventing cardiovascular disease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5216015A (en) * 1991-02-05 1993-06-01 Rhone-Poulenc Rorer Pharmaceuticals Inc. Compounds having hypocholesterolemic properties
WO2001000653A1 (en) * 1999-06-23 2001-01-04 Forbes Medi-Tech Inc. Conjugates of phytosterol or phytostanol with ascorbic acid and use thereof in treating or preventing cardiovascular disease

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
N.S.HABIB ET AL.: "Synthesis of some Heterocyclic Derivatives of beta-Sitosterol", ARCH.PHARM., vol. 323, 1990, WEINHEIM, pages 401 - 404, XP009041946 *

Also Published As

Publication number Publication date
NO20060632L (en) 2006-04-06
BRPI0412439A (en) 2006-09-05
CN1832957A (en) 2006-09-13
NZ545087A (en) 2009-10-30
EP1644399A2 (en) 2006-04-12
CA2531836A1 (en) 2005-01-20
KR20060052792A (en) 2006-05-19
RU2006103797A (en) 2006-07-27
WO2005005453A2 (en) 2005-01-20
AU2004255285A1 (en) 2005-01-20
MXPA06000326A (en) 2006-03-30
JP2007525470A (en) 2007-09-06
PL379516A1 (en) 2006-10-02

Similar Documents

Publication Publication Date Title
WO2005005453A3 (en) Novel compounds and compositions comprising sterols and/or stanols and cholesterol biosynthesis inhibitors and use thereof in treating or preventing a variety of diseases and conditions.
WO2006138163A3 (en) Anti-hypercholesterolemic compounds
TNSN08153A1 (en) Anti-hypercholesterolemic compounds
WO2006121861A3 (en) Biphenylazetidinone cholesterol absorption inhibitors
WO2005062824A8 (en) Anti-hypercholesterolemic compounds
WO2002058734A3 (en) Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions
PT1509232E (en) A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer`s disease
MY148480A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2002058731A3 (en) Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions
WO2004043456A8 (en) Cholesterol absorption inhibitors for the treatment of demyelination
WO2002058685A3 (en) Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications
MXPA04002167A (en) 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases.
AP2003002743A0 (en) Therapeutic combination of a cept inhibitor and atorvastatin
EP2332527A3 (en) Flavanoids and Isoflavanoids for the prevention and treatment of cardiovascular diseases
WO2005046603A3 (en) Pyridine compounds
WO2008073452A8 (en) Compositions, synthesis, and methods of using indanone based cholinesterase inhibitors
MX2009005691A (en) Inhibitors of diacylglycerol o-acylotransferase type 1 enzyme.
TW200509937A (en) Novel compounds and their use in therapy
WO2002058733A3 (en) Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications
WO2005046797A3 (en) Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
CA2602643A1 (en) Composition for improving blood cholesterol levels
WO2006001877A3 (en) Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
WO2008034796A3 (en) Estratriene derivatives and their uses as 17beta-hydr0xyster0id dehydrogenase inhibitors
MXPA06000705A (en) Combination of mglur2 antagonist and ache inhibitor for treatment of acute and/or chronic neurological disorders.
WO2006098761A3 (en) Hsp90 inhibitors, methods of making and uses therefor

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480022866.7

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006517922

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 2531836

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1020067000470

Country of ref document: KR

Ref document number: PA/a/2006/000326

Country of ref document: MX

Ref document number: 2004255285

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 545087

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2004255285

Country of ref document: AU

Date of ref document: 20040709

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 200601149

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2006103797

Country of ref document: RU

Ref document number: 2004737936

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004737936

Country of ref document: EP

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWP Wipo information: published in national office

Ref document number: 1020067000470

Country of ref document: KR

ENP Entry into the national phase

Ref document number: PI0412439

Country of ref document: BR

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载